208 SynthEtic LEthal Cancer Therapy in mesothelioma (SELECTmeso): a molecularly stratified multi-arm phase II platform trial for patients with relapsed malignant mesothelioma

Mesothelioma is a rare cancer caused by exposure to asbestos typically affecting the pleura or pericardium. Prognosis remains dismal yet targeted therapies are lacking. Advances have revealed a preponderance of tumour suppressors in mesothelioma, which may present new opportunities to develop treatments. The SELECTmeso trial platform, coordinated by the Cancer Research UK Southampton Clinical Trials Unit, has been developed to leverage new insights into synthetic lethal biology to improve treatment outcomes.

Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Kayleigh Hill, Dean Fennell, Anna Song, Robin Wickens, Judith Cave, Andrea Corkhill, Jens Hahne, Michelle Lattimore, Peter Wells-Jordan, Nada Nusrat, Sean Dulloo, Charlotte Poile, Gareth Griffiths Tags: Trials in progress Source Type: research